Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Is Value-Based Healthcare Here to Stay? Looking for Answers in New Policies

2,698 views

Published on

Healthcare leaders are eager for a modicum of clarity when it comes to the industry’s shift to value-based healthcare given the uncertainties of Congress and the new Administration.

Fortunately, an analysis of three key pieces of information tells us value-based healthcare is likely here to stay:

The 21st Century Cures Act (Cures).
The Executive Order on reducing the “burden” of the Affordable Care Act (ACA).
Tom Price’s comments at his confirmation hearings.

It is a relatively safe bet that value-based healthcare delivery and payment programs will continue to be supported by federal law and regulation for several reasons:

Bipartisan support: The success of Cures indicates that bipartisan cooperation will continue on key healthcare issues.
Market-based innovation: The emerging evidence is that Congress and the Administration will support innovation in payment and delivery models.
Support for Existing ACA Innovation programs: Although highly uncertain, there are some indications that not all of the ACA will be scrapped.

Published in: Healthcare
  • Be the first to comment

Is Value-Based Healthcare Here to Stay? Looking for Answers in New Policies

  1. 1. Is Value-Based Healthcare Here to Stay? Looking for Answers in New Policies Daniel Orenstein
  2. 2. © 2016 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Is Value-Based Healthcare Here to Stay? Looking for Answers in New Policies The final days of 2016 were fraught with uncertainty about what Congress and the new Trump Administration would do to the Affordable Care Act (ACA) and the healthcare regulatory landscape overall. So far, in 2017, we do not have much more clarity. Repeal, repeal and replace, repeal and delay, modify without repeal—there are now even more questions than answers and still no consensus Republican plan in sight.
  3. 3. © 2016 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Is Value-Based Healthcare Here to Stay? Looking for Answers in New Policies Yet healthcare executives would certainly appreciate some modicum of clarity, at least on the narrower topic of whether the shift to value-based healthcare models will continue under whatever new system is coming. This presentation attempts to add clarity by analyzing what we know so far, as reflected in the limited actual evidence that is available.
  4. 4. © 2016 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Is Value-Based Healthcare Here to Stay? Looking for Answers in New Policies I will do my best to describe where things may be going for value- based care (VBC) reform, as well as the analytic and other health information technology (HIT) systems required to support it, by analyzing the three key pieces of information we have so far: 1. Enactment of the 21st Century Cures Act (Cures). 2. Executive Order on reducing the “burden” of the ACA. 3. Tom Price’s comments at his confirmation hearings.
  5. 5. © 2016 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. #1 The 21st Century Cures Act You may be wondering what Cures has to do with VBC. The fact is, this wide-ranging bill passed with almost universal bipartisan support. Taken together with the reality that value-based payment programs have historically enjoyed broad bipartisan support, the passage of Cures indicates that policies with bipartisan support will continue to move forward.
  6. 6. © 2016 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. #1 The 21st Century Cures Act Why did Cures happen even though the ACA continues to be so politically contentious? Because the ACA brings into play some of the most entrenched ideologies of both parties— the involvement of the public versus the private sector in health insurance markets, entitlements, and entitlement reform. Cures is non-ideological, involving commonsense policies on accelerating drug discovery, helping providers and patients, and requiring information to flow more freely.
  7. 7. © 2016 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. #2 The Executive Order Widely viewed as mostly a symbolic act to show action on “repealing” the ACA, it asks the executive branch and HHS to: i. take steps to minimize the “burdens” of the ACA, and ii. waive, defer, grant exemptions from, or delay provisions of the ACA. On January 20, 2017, President Trump signed an Executive Order on “minimizing the economic burden” of the ACA.
  8. 8. © 2016 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. #2 The Executive Order Other provisions of the order tie these actions to giving states “more flexibility and control to create a more free and open healthcare market.” A subsequent provision also reiterates the concept of creating a free and open market for healthcare services. The principle of market innovation is therefore prominent in the Executive Order and implies promotion of innovative techniques and programs, including innovation in payment programs.
  9. 9. © 2016 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. #3 Tom Price’s Comments In his confirmation hearings nominee Tom Price, made comments regarding portions of the ACA that promote programs aimed at innovation in healthcare delivery and VBC. Notably, Price indicated support in principle the activities of the Center for Medicare and Medicaid Innovation (CMMI), which was established by the ACA to test and promote innovative payment and delivery system models that have the potential to improve the quality of care. TOM PRICE U.S. Secretary of Health and Human Services
  10. 10. © 2016 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. #3 Tom Price’s Comments While Price does not support all CMMI activities, he supports the mission of CMMI in principle, which is essentially a test bed for VBC programs. This provides another indication that these programs may continue to enjoy support in the Trump Administration with Price as Secretary of HHS. TOM PRICE U.S. Secretary of Health and Human Services
  11. 11. © 2016 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Pulling the Threads Together to Evaluate the Status of Value-Based Healthcare There is no doubt that this analysis still fits squarely in the category of “reading the tea leaves”—evidence of the shape of future healthcare reform is scant. But the evidence that exists appears to support the principles that are preconditions to value-based healthcare programs: Bipartisan support Market based innovation Support for Existing ACA Innovation programs > > >
  12. 12. © 2016 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Pulling the Threads Together to Evaluate the Status of Value-Based Healthcare Bipartisan support: The success of Cures indicates that bipartisan cooperation will continue on key healthcare issues, notwithstanding the extreme ideological divide on market and entitlement related healthcare issues. Value-based payment programs have historically fallen into the non- ideological, bipartisan category.
  13. 13. © 2016 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Pulling the Threads Together to Evaluate the Status of Value-Based Healthcare Market-based innovation: The emerging evidence is that Congress and the Administration will support innovation in payment and delivery models, and flexibility in programs that will be included for participation in federal payment programs, which will flow through to commercial payment programs.
  14. 14. © 2016 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Pulling the Threads Together to Evaluate the Status of Value-Based Healthcare Support for Existing ACA Innovation programs: Although highly uncertain, there are some indications that not all of the ACA will be scrapped. And in this case, the innovative payment and delivery programs, which are on the non- ideological side, may be among those pieces of the ACA that will survive and be supported in some form.
  15. 15. © 2016 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Value-Based Healthcare and Payment Programs Are Likely Here to Stay Looking at what has transpired to date in 2017 with the new Congress and Administration, it is a relatively safe bet that value-based healthcare delivery and payment programs will continue to be supported by federal law and regulation. It is also worth observing that, even without federal support, there is tremendous momentum for VBC in the private healthcare market. Therefore, it appears likely that, whatever the ultimate shape that healthcare reform takes, value- based healthcare (and the infrastructure required to support it) is here to stay.
  16. 16. © 2016 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. For more information: “This book is a fantastic piece of work” – Robert Lindeman MD, FAAP, Chief Physician Quality Officer
  17. 17. © 2016 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. More about this topic Link to original article for a more in-depth discussion. Is Value-Based Healthcare Here to Stay? Looking for Answers in New Policies Why the 21st Century Cures Act Is Great News for Healthcare Daniel Orenstein, General Counsel The Key to Transitioning from Fee-for-Service to Value-Based Reimbursement Bobbi Brown, VP of Financial Engagement; Jared Crapo, VP Why You Need to Understand Value-Based Reimbursement and How to Survive It Bobbi Brown, VP of Financial Engagement Healthcare Interoperability: New Tactics and Technology Sean Stohl, Analytics, SVP Healthcare Information Systems: A Look at the Past, Present, and Future Larry Grandia, Consultant
  18. 18. © 2016 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Prior to joining Health Catalyst Dan Orenstein was at athenahealth, Inc. (NASDAQ: ATHN) for 10 years, the last 7 as General Counsel and Secretary. Prior to that, Dan practiced in the areas of corporate, intellectual property, and healthcare law with law firms in Boston and Washington, D.C. He has written and presented on health care law and IT topics throughout his career. He also served as a leader of the American Health Lawyers Association’s Health IT practice group. Other Clinical Quality Improvement Resources Click to read additional information at www.healthcatalyst.com

×